Paris / Toulouse, France – [March 2026] – Plantibodies and Orius today announced that their collaborative project, PhytomAbs, has been selected under France 2030’s “Innovations in Biotherapies and Bioproduction” call for projects. The project aims to advance a new generation of plant-based oral biologics for inflammatory bowel disease (IBD), while establishing scalable bioproduction capabilities in France.
PhytomAbs brings together complementary expertise in biotechnology, pharmaceutical development, and controlled-environment plant production. The platform is designed to produce monoclonal antibodies in plants, preserve their biological activity through gastrointestinal transit, and enable targeted release in the colon.
Combining pharmaceutical development and scalable plant bioproduction
Plantibodies will lead the pharmaceutical and translational development activities, including formulation, analytical characterization, and preclinical evaluation through in vitro and in vivo studies.
Orius will contribute its expertise in upstream plant bioproduction, focusing on cultivation process optimization, standardization of plant material, and scale-up in controlled environments suited to healthcare industry requirements.
Together, the partners aim to build an integrated platform connecting the development of oral biologics with robust, reproducible manufacturing processes. For Plantibodies, the project will strengthen its technology platform and support preclinical development and future transfer to processes meeting pharmaceutical standards. For Orius, it represents a step toward establishing a French plant development and production platform capable of supporting other biotechnology and pharmaceutical companies.
Strengthening bioproduction capabilities in France and Europe
PhytomAbs also addresses the strategic need to strengthen French and European capabilities in biotherapeutics. By developing a domestic pharmaceutical plant bioproduction ecosystem, the project aims to complement established cell-based manufacturing systems, reduce reliance on overseas production capacity, and support the future supply of strategically important biologics.
Advancing oral treatment options for gastrointestinal diseases
For patients living with IBD, PhytomAbs aims to contribute to the development of oral treatments that are easier to use, more accessible, and designed to act locally in the gastrointestinal tract.
This approach could ultimately improve quality of life and reduce the burden of treatment. Beyond IBD, the platform is intended to provide a reusable technological and industrial foundation for developing targeted oral biologics for a broader range of gastrointestinal diseases.
Management comments
“Being selected under this France 2030 call for projects is an important recognition of Plantibodies and our vision: to develop a new generation of oral biologics for gastrointestinal diseases in France, at the intersection of biotechnology, pharmaceutical development, and bioproduction. With Orius, we bring together highly complementary expertise to accelerate the translation of this innovation into tangible applications for patients.”
— Pierre Bauër, CEO and Co-founder of Plantibodies
“PhytomAbs is a natural extension of our expertise in cultivating high-value plants into human health. Our goal is to build Europe’s first plant production platform meeting pharmaceutical standards, capable of supplying clinical batches of plant material to the pharmaceutical industry. France 2030 support gives us the means to turn this ambition into reality.”
— Paul-Hector Oliver, CEO and Co-founder of Orius
About Plantibodies
Plantibodies develops oral biologics targeting the gastrointestinal tract. The company combines biotechnology, formulation, and preclinical development to advance a new generation of treatments for gastrointestinal diseases. Its approach brings together therapeutic innovation, pharmaceutical standards, and a focus on meaningful benefits for patients.
About Orius
Orius cultivates high-value botanical species in France for the cosmetics, nutraceutical, space, and pharmaceutical industries. The company combines horticultural innovation with advanced production technologies to deliver plant materials with optimized chemical composition, traceability, and standardized quality.
Press contacts
Plantibodies
Pierre Bauër – CEO and Co-founder
pierre.bauer@plantibodies.tech
Orius
Paul-Hector Oliver – CEO and Co-founder
ph.oliver@orius.co
